EOM Pharmaceutical Holdings Stock Price, News & Analysis
IMUC
OTC Link
Company Description
Immunocellular Therapeutics, Ltd. is a Los Angeles-based clinical-stage company developing immune-based therapies for brain and other cancers. They've completed phase 2 trials for ict-107, targeting glioblastoma stem cells and have projects like ict-121, ict-140, and stem-to-t-cell research.
Stock Performance
Latest News
SEC Filings
No SEC filings available for EOM Pharmaceutical Holdings.
Financial Highlights
$0
Revenue (TTM)
-$306,704
Net Income (TTM)
-$2,173,997
Operating Cash Flow
9.53
-$307,090
Upcoming Events
Short Interest History
Last 12 Months
Loading short interest data...
Days to Cover History
Last 12 Months
Loading days to cover data...
Frequently Asked Questions
What is the current stock price of EOM Pharmaceutical Holdings (IMUC)?
The current stock price of EOM Pharmaceutical Holdings (IMUC) is $0.0899 as of October 15, 2025.
What is the market cap of EOM Pharmaceutical Holdings (IMUC)?
The market cap of EOM Pharmaceutical Holdings (IMUC) is approximately 11.3M. Learn more about what market capitalization means .
What is the revenue (TTM) of EOM Pharmaceutical Holdings (IMUC) stock?
The trailing twelve months (TTM) revenue of EOM Pharmaceutical Holdings (IMUC) is $0.
What is the net income of EOM Pharmaceutical Holdings (IMUC)?
The trailing twelve months (TTM) net income of EOM Pharmaceutical Holdings (IMUC) is -$306,704.
What is the operating cash flow of EOM Pharmaceutical Holdings (IMUC)?
The operating cash flow of EOM Pharmaceutical Holdings (IMUC) is -$2,173,997. Learn about cash flow.
What is the current ratio of EOM Pharmaceutical Holdings (IMUC)?
The current ratio of EOM Pharmaceutical Holdings (IMUC) is 9.53, indicating the company's ability to pay short-term obligations. Learn about liquidity ratios.
What is the operating income of EOM Pharmaceutical Holdings (IMUC)?
The operating income of EOM Pharmaceutical Holdings (IMUC) is -$307,090. Learn about operating income.
What is Immunocellular Therapeutics, Ltd. focused on?
They are developing immune-based therapies for brain and other cancers.
What is the lead product candidate of Immunocellular?
Ict-107 is a dendritic cell-based immunotherapy targeting tumor-associated antigens on glioblastoma stem cells.
What other projects are in Immunocellular's pipeline?
They have projects like ict-121, ict-140, and the stem-to-t-cell research program.
Where is Immunocellular Therapeutics, Ltd. based?
They are based in Los Angeles.
What phase of trials has ict-107 completed?
Ict-107 has concluded phase 2 trials.
What is the significance of ict-121?
Ict-121 is a dendritic cell immunotherapy targeting the cd133 antigen on stem cells in recurrent glioblastoma.
What is the focus of ict-140?
Ict-140 is a dendritic cell immunotherapy targeting antigens on ovarian cancer stem cells.
What is the stem-to-t-cell research program about?
It engineers the patient's hematopoietic stem cells to generate antigen-specific cancer-killing t-cells.